The FDA sent warning letters to 30 telehealth companies for making "false or misleading claims" about compounded GLP-1 drugs -- the cheaper, non-FDA-approved versions of semaglutide and tirzepatide that have fueled the weight-loss drug boom [1]. The letters, issued March 3, represent the second major round of enforcement after 55 similar warnings in September 2025 [2].

The firms marketed compounded versions of Ozempic and Mounjaro using language that implied FDA approval where none existed. Some promoted compounded semaglutide as equivalent to Novo Nordisk's branded product. The FDA was explicit: "Compounded drugs are not FDA-approved. This means the agency does not review their safety, effectiveness or quality before they are marketed" [1].

The most prominent casualty has been Hims & Hers, which pulled its compounded semaglutide pill in February after an FDA crackdown and subsequently entered a partnership with Novo Nordisk to offer the branded product instead [3]. Reuters reported the pivot as the clearest sign that the compounded GLP-1 market's regulatory window is closing [4].

The stakes extend beyond the firms themselves. Compounded GLP-1s were the affordable entry point for millions of patients priced out of branded drugs costing $1,000+ per month. Shutting down the compounding pipeline without addressing the underlying price problem leaves patients with a choice between unregulated products and unaffordable ones.

-- Nora Whitfield, Chicago